1F-LSD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1F-LSD, also known as 1-(furan-2-carbonyl)-LSD, 1-(2-furoyl)-LSD, or SYN-L-005, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is thought to act as a prodrug of LSD.[1][2] The drug interacts with serotonin receptors, including the serotonin 5-HT2A receptor, and produces the head-twitch response in rodents, with about 3-fold lower potency than LSD.[1] It hydrolyzes into LSD in rodents.[1] 1F-LSD was patented in 2024[2] and was first described in the scientific literature in 2025.[1] It has been encountered as a novel designer drug in Germany and Japan.[1]
- None
 | |
| Clinical data | |
|---|---|
| Other names | 1-(Furan-2-carbonyl)-LSD; 1-(2-Furoyl)-LSD; SYN-L-005; N,N-Diethyl-1-(furan-2-carbonyl)-6-methyl-9,10-didehydroergoline-8β-carboxamide |
| Routes of administration | Oral |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C25H27N3O3 |
| Molar mass | 417.509 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
Interactions
Chemistry
Society and culture
Legal status
Canada
1F-LSD is not an explicitly nor implicitly controlled substance in Canada as of 2025.[3]
United States
1F-LSD is not an explicitly controlled substance in the United States.[4] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.